Award Number: W81XWH-10-1-0894

TITLE: Multicenter Clinical Trial of Keratin Biomaterials for Peripheral Nerve Regeneration

PRINCIPAL INVESTIGATOR: Zhongyu Li, M.D., Ph.D.

CONTRACTING ORGANIZATION: Wake Forest University
                        Winston Salem, NC 27157

REPORT DATE: October 2013

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
               Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;
                        Distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and
should not be construed as an official Department of the Army position, policy or decision
unless so designated by other documentation.
Common injuries sustained by war fighters in Iraq and Afghanistan result from blast and shrapnel wounds which cause extensive damage to skin, bones, and nerves. The management of damaged peripheral nerves is challenging for patients and surgeons. Peripheral nerve transection injuries may fail to regenerate even when managed surgically. These injuries are associated with long term disability and impaired function. Nerve guidance conduits have been developed for use in surgery to bridge the gap between transected nerve ends and to support nerve regeneration. A team of scientist and clinicians at Wake Forest School of Medicine has developed a keratin biomaterial hydrogel that can be used as luminal filler in nerve guidance conduits to facilitate nerve regeneration. Studies in mice, rabbits, and nonhuman primates have established the feasibility of this keratin hydrogel to promote nerve regeneration. A Phase I prospective, randomized trial is designed to compare nerve regeneration in patients sustaining peripheral nerve injuries treated either with keratin hydrogel and a nerve conduit or with a nerve conduit alone. The clinical trial will be initiated as soon as the FDA provides an IND for the keratin biomaterial hydrogel.

Peripheral nerve transection, nerve conduit, nerve repair, keratin biomaterial hydrogel, clinical trial
# Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Introduction</td>
<td>4</td>
</tr>
<tr>
<td>Body</td>
<td>4-5</td>
</tr>
<tr>
<td>Key Research Accomplishments</td>
<td>5</td>
</tr>
<tr>
<td>Reportable Outcomes</td>
<td>9</td>
</tr>
<tr>
<td>Conclusion</td>
<td>10</td>
</tr>
<tr>
<td>References</td>
<td>11</td>
</tr>
<tr>
<td>Appendices</td>
<td>NA</td>
</tr>
</tbody>
</table>
INTRODUCTION

While body armor, advanced resuscitation techniques, rapid transportation of wounded soldiers, and damage control surgery have made major contributions to saving lives on the battlefield, more can be done to improve the outcomes for soldiers who sustain extremity injuries such as traumatic nerve transections. Extremity trauma with nerve injury can be associated with long term functional limitations and impairments (Rosen 2000; Ruijs 2005). Damaged peripheral nerves may fail to regenerate in patients even when they are managed by surgical intervention. The use of sensory nerve autografts for nerve repair is considered to be the “gold standard”; however, this procedure is associated with donor site morbidity and the possibility that there may be insufficient donor nerve available for extensive repairs involving several nerves (Lohmeyer 2009).

To avoid the issues associated with the use of autografts, nerve guidance conduits have been developed to bridge the gap between the transected nerve ends and to support nerve regeneration (Taras 2008). A team of scientists and clinicians at Wake Forest School of Medicine has developed a keratin biomaterial hydrogel that can be used as luminal filler in nerve guidance conduits in order to facilitate nerve regeneration. Preliminary studies in mouse, rat, rabbit and non-human primate models have established the feasibility and clinical relevance of using a keratin biomaterial filler to promote nerve regeneration (Apel 2008, Hill 2011, Lin 2012, Sierpinski 2008, Pace submitted).

The objective of the clinical trial is to conduct a combined Phase I prospective randomized two center trial that will follow patients who are treated for traumatic peripheral nerve transections. Patients will be randomized to one of two treatment groups in order to compare nerve regeneration following two methods of nerve repair. One group of patients will undergo nerve repair using the keratin hydrogel as filler for a commercially available nerve conduit, and the other group will undergo nerve repair using nerve conduit alone. This trial also will document the safety of the keratin hydrogel. The specific aim of this clinical trial is to determine the safety and efficacy of keratin hydrogel biomaterial as luminal filler in nerve conduits used to manage traumatic peripheral nerve transection.

BODY

After many months of communications between KeraNetics and the FDA, the KeraNetics nerve product was designated as a biologic and a requirement for an Investigative New Drug (IND) was imposed by the FDA. KeraNetics has disagreed with this designation thereby requiring the development of a new regulatory strategy. Rather than file a company sponsored IND lead by KeraNetics, the team proposed to file an investigator-initiated IND on behalf of the CDMRP funded principal investigator, Zhongyu Li, MD, PhD. On November 8, 2012 Dr. Van Dyke conducted a conference call with the FDA to explain this change. The FDA agreed to evaluate an IND submitted under this arrangement. The team at Wake Forest School of Medicine believes that they will be able to meet the requirements of the FDA, both for filing the investigator-initiated IND as well for manufacturing and supplying the product needed for the clinical trial.

As of February 1, 2013 Dr. Van Dyke moved his primary faculty appointment from Wake Forest to Virginia Polytechnic Institute and State University (Virginia Tech) in Blacksburg, Virginia. The plan was to use a laboratory under development by Dr. Van Dyke at Virginia Tech to produce and characterize the keratin hydrogel. However, this plan could not be
developed. Therefore, KeraNetics now will be producing the keratin hydrogel needed for the study. In addition, the fate and distribution studies will be performed by Toxicon. Currently, we are working with Toxicon to determine the most appropriate animal model protocol to evaluate the fate and distribution of keratin hydrogel to satisfy the FDA requirements for an IND. In addition, through Toxicon we are working with Perkin Elmer to radiolabel the keratin hydrogel to complete these fate and distribution studies. It should be noted that these steps will streamline the commercialization process.

Because of these changes, we are developing a new statement of work and budget to reflect the FDA-requested preclinical work in order to obtain a designation from the FDA. This revised statement of work will also include a description of the clinical trial part of the project. This revised statement of work will be developed in anticipation that further interactions with the FDA may result in modifications in the approval process based on the outcome of the fate and distribution studies and purity and potency assays.

In addition, KeraNetics has agreed to provide documents to outline the parameters of the partnership between their company and Wake Forest School of Medicine and to detail their support of the project. The revised statement of work and budget will be submitted to Ayi Ayayi, USAMRAA Contract Specialist. The proposed changes have also been discussed with Miriam R. Darnell, PhD, Grants officer’s Representative during a series of conference calls.

As soon as the IND is available, our team will be able to obtain final approval for the study protocol from the Copernicus Group, an independent review board that has previously granted conditional approval for the protocol. Then, the protocol will be submitted to the University of Virginia School of Medicine IRB (the second study site) and the HRPO for approval.

The Standard Operating Procedures (SOP) Manual and study data forms will be finalized. Training of study personnel at both study sites will be completed, and the study protocol will be initiated at both study sites.

KEY RESEARCH ACCOMPLISHMENTS

- Pre-IDE package submitted to the FDA, June 8, 2010.
- September 28, 2010: Submission of the clinical protocol to the Copernicus Group, an independent IRB located in Research Triangle Park, North Carolina. Due to the conflict of interest policies at the Wake Forest School of Medicine, Dr. Li was asked to send the protocol to an independent review board.
- October 13, 2010: The Copernicus Group granted conditional approval of both Phase 0 and Phase I/II protocols pending the assignment of an IDE number or confirmation of 510K justification acceptance from the FDA.
- October 18, 2010: FDA feedback provided to Dr. Li and Dr. Van Dyke indicated that the FDA’s main concern was whether the keratin hydrogel should be classified as a device or a biologic. The FDA suggested that a meeting between the FDA and Drs. Li and Van Dyke should take place; however, the primary reviewer at the FDA was unable to identify a date for a meeting.
- A Request for Designation (RFD) was submitted to the FDA in May 3, 2011. Based on this submission date, the FDA had until July 9, 2011 to reply to the request.
- July 7, 2011: The FDA designated the keratin hydrogel biomaterial as a “therapeutic biological product.” The product has been assigned to the Center for Drug Evaluation and
Research (CDER) as the lead agency for premarket review and regulation based on the keratin hydrogel’s primary mode of action.

- On July 18, 2011, there was a conference call with Miriam Darnell, PhD, Science Officer for Grants Management and the investigators at Wake Forest (Zhongyu Li, MD, PhD, Mark Van Dyke, PhD, and Beth Paterson Smith, PhD). During the call, the submission of the pre-IND package to the FDA and the scheduling of a pre-IND meeting with the FDA were discussed. In addition, the expected request by the FDA for a fate and distribution study of the keratin hydrogel was discussed. Because funding will be required to complete these studies, possible funding sources were discussed.

- July 25, 2011: Dr. Darnell sent an email regarding the possibility of re-budgeting the grant funding to cover the estimated $250,000 required for the fate and distribution studies in an animal model. Dr. Darnell requested a written statement describing the anticipated animal study, the requirement for the study, the study timeline, and any other pertinent information. These issues also need to be discussed with Ms. Susan Dellinger, the USAMRAA Grants Officer who has the final authority on issues of statement of work and budgets.

- July 25, 2011: Dr. Van Dyke responded to Dr. Darnell’s email to provide information that a contract research organization (CRO) had been contacted regarding a quote to cover the costs of the fate and distribution study. Dr. Van Dyke also outlined the reasons why he requested a representative from CDMRP be present at the pre-IND meeting with the FDA.

- July 26, 2011: Dr. Van Dyke sent an email to Dr. Darnell describing the fate and distribution studies including the four to six month period needed to complete the study at a cost of approximately $250,000.

- August 1, 2011: An email was sent to Brian Garland, Administrative Coordinator of the Human Research Protection Office at USAMRMC containing the June 23, 2011 Clinical Trial Quarterly Technical Progress Report to provide him with the status of our progress on the clinical trial.

- August 8, 2011: The request for a pre-IND meeting with the FDA was submitted.

- On August 19, 2011, Dr. Darnell sent an email to Christopher Baker, CIV USA MEDCOM USAMRAA regarding the request for re-budgeting to cover the costs of preclinical animal studies to determine the fate and distribution of the keratin hydrogel. On August 23, 2011, Mr. Baker requested a revised budget and statement of work for consideration.

- Beginning August 23, 2011, we worked with our Office of Research to develop the re-budgeting plan and statement of work required to complete the keratin hydrogel fate and distribution studies.

- August 31, 2011: The FDA sent a letter providing the date for the pre-investigational new drug application of KeraGenics Nerve. The meeting was scheduled for November 8, 2011 from 12:00-1:00 p.m. in Silver Spring, Maryland. Miriam Darnell, PhD the Science Officer for Grants Management and LTC(P) Leggit, the director of CDMRP agreed to attend this meeting.

- October 7, 2011: The Type B meeting package for KeraNetic’s KeraGenics™ Nerve (PIND No. 113077) was sent to Ms. Daughterty at the FDA.

- October 31, 2011: The attorneys at Hogan Lovells received a telephone call from the FDA cancelling the FDA meeting scheduled for November 8, 2011. This meeting cancellation occurred because the FDA was uncertain about how to coordinate our request for the nerve application for the keratin hydrogel given that there was a co-pending application for a keratin product for use in burn patients. The FDA determined a path for the burn device and
is now working on the designation of the nerve application to be used in our clinical trial to study nerve regeneration. An internal FDA meeting was scheduled for January 8, 2012. After this meeting, feedback is expected regarding our request for designation of the keratin hydrogel for use in nerves.

- **March 9, 2012:** Dr. Van Dyke emailed Dr. Darnell to update her on the conversations he had with the FDA. The FDA is involved in internal discussions regarding the designation of the keratin biomaterial hydrogel. The FDA has scheduled a meeting for March 26, 2012 to finalize recommendations on the designation of the keratin biomaterial.

- **May 1, 2012:** Dr. Van Dyke and Dr. Luke Burnett (KeraNetics) met at the FDA with representatives from the Center for Drug Evaluation Research (CDER), the Center for Biologics Evaluation Research (CBER), and the Center for Devices and Radiological Health (CDRH) to clarify the designation of the keratin hydrogel. During this meeting, the parties agreed on the next steps required for an IND package for the keratin biomaterial hydrogel.
  a. The subcutaneous injection trial (Phase 0) was eliminated from the trial design. The FDA determined that the Phase 0 trial was unnecessary.
  b. Preparation of the keratin hydrogel for use in the clinical trial was discussed. The nerve conduits will be prefilled with keratin; these prefilled conduits will be lyophilized and packaged for terminal sterilization. The use of the prefilled conduits will allow the surgeon to rehydrate the conduit a few minutes prior to implantation. The FDA agreed that this preparation was appropriate because they prefer terminal sterilization of products.
  c. The FDA agreed on the following purity and potency assays to be completed before beginning the Phase I clinical trial: 1) analytical tests to determine purity (size exclusion chromatography for molecular weight, amino acids analysis, ELISA for protein identification, and gel rheology) and 2) a cell adhesion assay using a rat Schwann cell line to determine the potency of the hydrogel.
  d. The FDA discussed their preferred experimental design for preclinical animal testing. FDA agreed to review the preclinical data from KeraNetics.
  e. The FDA agreed on the design of the fate and distribution study. Labeled keratin gel will be placed inside nerve conduits. The ends of the conduits will be closed, and the conduits will be implanted in rat muscle. The rats will be followed to determine the fate and distribution of the labeled keratin biomaterial hydrogel. Depending on the outcomes of this study, additional pharmacokinetic studies may be warranted. The FDA will review the results of the fate and distribution study and will determine if any additional studies will be required.

- **May 31, 2012:** A revised SOW and budget to reflect the extra funds needed to complete the testing required by the FDA were developed. Wake Forest agreed to provide funding up to the difference of $107,244 between the total costs of the required studies ($363,244) and the $256,000 available from the CDMRP. A letter confirming this arrangement between CDMRP and Wake Forest School of Medicine was sent to Dr. Darnell. In addition, documents were provided to document the breakdown of costs, the timeline for performance of preclinical work for the FDA, and the cost sharing information provided by KeraNetics.

- **June 29, 2012:** A request was submitted to CDMRP requesting additional funding to perform the purity and potency assays and the fate and distribution studies on the keratin hydrogel.

- **July 22, 2013:** A conference call was made to Miriam R. Darnell, PhD by Zhongyu Li, MD, PhD, L. Andrew Koman, MD and Beth Paterson Smith, PhD. Drs. Koman, Li, and Smith
expressed their concerns regarding the designation of the keratin hydrogel as a drug versus a device. These concerns are related to the time it has taken the FDA to determine the designation of the keratin hydrogel based on the FDA’s response to the keratin used for burn applications versus keratin used for nerve regeneration. Therefore, Drs. Li, Koman, and Smith asked for assistance from Dr. Darnell’s group for moving the FDA process forward in order to identify a pathway for designation of the keratin hydrogel for use in the proposed nerve studies.

- July 25, 2013: Dr. Darnell sent an email to Drs. Li, Koman, and Smith with information that she had a discussion with a regulatory expert at another agency at USAMRMC about the proposed study and the FDA regulatory pathway. He was given documents and will provide his assessment on the information. Dr. Darnell also requested documentation from Drs. Li, Koman, and Smith to support the continued relevance of repairing a two cm nerve gap.

- August 1, 2013: An email was sent to Dr. Darnell with an attachment containing a summary of the recent literature on nerve repairs and information regarding the question about the relevance of repairing a two cm nerve gap.

- August 6, 2013: An email was sent to Dr. Darnell that included several points regarding FDA designation from Mark Van Dyke, PhD.

- Further work on the clinical trial cannot be performed until clarification regarding the designation of the keratin hydrogel is provided to Dr. Li and his research team by the FDA.
REPORTABLE OUTCOMES

Publications


Presentations


Barnwell J, Pace L, Li Z, Koman LA, Smith T, Van Dyke M. Peripheral nerve regeneration using keratin biomaterials: From bench to bedside. Biomedical Engineering Society Annual Meeting. Austin, TX. October 6-9, 2010

**Posters**


"Cellular Interactions with a Human Hair Keratin Hydrogel Enhance Peripheral Nerve Regeneration" Wake Forest Graduate School of Arts and Sciences Graduate Student Research Day: Winston-Salem, NC 3/2010

**CONCLUSIONS**

Significant progress has been made in working with the FDA to obtain the IND necessary to begin the Phase I clinical trial. Our team now has clear direction from the FDA of the steps that must be taken to comply with their recommendations for the IND. In addition, Wake Forest School of Medicine and the CDMRP worked together to identify the funding necessary to complete the studies requested by the FDA. As soon as the FDA provides the IND for the keratin biomaterial hydrogel, final approval of the clinical study protocol will be obtained from Copernicus (the independent review board), Wake Forest School of Medicine, the University of Virginia School of Medicine, and HRPO. Following IRB approval, the clinical trials will be initiated.

**REFERENCES**


APPENDICES

None